Evidence map›Paper›PMID 41398883›Full record

ReviewMedicine2025

Fatal interstitial lung disease associated with rituximab in diffuse large B-cell lymphoma: A case report and literature review.

Li Li, Fei Liu, Jie Zhou, Xiang-Lei Chen

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Li LiDepartment of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China.ORCID 0009-0008-0592-3740
Fei LiuDepartment of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China.
Jie ZhouDepartment of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China.
Xiang-Lei ChenDepartment of Hematology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China.ORCID 0000-0003-1607-9967

Funding

Weifang Science and Technology Development Program 2025YX098
6 · The paper itself

Abstract

rationaleRituximab-associated interstitial lung disease (ILD) may initially be asymptomatic, and serial monitoring of serum tumor necrosis factor-alpha levels may facilitate timely diagnostic intervention with pulmonary computed tomography. PATIENT CONCERNS: A 73-year-old patient with diffuse large B-cell lymphoma (DLBCL) developed ILD during treatment with a rituximab-containing regimen. DIAGNOSES: Rituximab-associated interstitial disease was made.

interventionsThe patient was treated with corticosteroids, intravenous immunoglobulin, and antifibrotic therapy. OUTCOMES: The ILD progressed, and the patient ultimately succumbed to type I respiratory failure. LESSONS: Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.

Indexed as

Antineoplastic Agents, ImmunologicalLung Diseases, InterstitialLymphoma, Large B-Cell, DiffuseRituximabAgedFatal OutcomeHumansMaleTomography, X-Ray ComputedAntineoplastic Agents, ImmunologicalRituximabfatalinterstitial lung diseaserituximabTNF-α

Identifiers

PMID41398883
PMCPMC12708094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.